News for Healthier Living

Patients with Large Territory STEMI and High Thrombus Burden Do Not Benefit from Intracoronary Delivery of Low-dose Fibrinolytics During PCI

Results from the multicenter, randomized, double-blind, placebo-controlled STRIVE trial found that low doses of recombinant tPA (alteplase) in patients with large-territory STEMI and high thrombus burden undergoing primary percutaneous coronary intervention (PCI) did not improve outcomes.

October 28, 2025


November 5 2025

November 4 2025

November 3 2025

November 2 2025

November 1 2025

October 31 2025

October 30 2025

October 29 2025

October 28 2025

October 27 2025

October 26 2025

October 25 2025

October 24 2025

October 23 2025